Abstract: A medicinal cannabis mixture has cannabis oil and one or more transdermal agents that increase permeability of skin to passage of cannabis. In a process of administering the mixture the solution is applied to a subject's skin over an artery.
Abstract: Described herein are compositions for treating dermatological conditions, such as skin conditions, as well as neuropathological conditions and disorders, particularly those requiring relief from pain and physical discomfort. The compositions as described may be topically or transdermally administered. In some aspects, the compositions and products comprise a pharmaceutically acceptable amount of at least one analgesic component and a cannabis component and are useful to relieve acute or chronic pain, inflammation, and the like, following application.
Type:
Application
Filed:
April 28, 2020
Publication date:
November 5, 2020
Applicant:
VCP IP HOLDINGS, LLC, LIMITED LIABILITY COMPANY DELAWARE
Abstract: Presented herein are methods for treating diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
Abstract: A pharmaceutical composition for preventing and treating liver diseases, includes cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.
Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-001 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-001 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing ?-rays, ?-rays, ?-rays, neutron radiation, or a combination thereof.
Abstract: Provided herein are therapeutic methods, kits, and pharmaceutical compositions for protecting a subject from radiation using a therapeutic agent selected from the group consisting of RRx-OO1 and a pharmaceutically acceptable salt thereof. One exemplary therapeutic method involves administering RRx-OO1 to the subject prior to the subject being exposed to the radiation, in order to protect the subject against radiation, such as ionizing radiation containing ?-rays, ?-rays, ?-rays, neutron radiation, or a combination thereof.
Type:
Application
Filed:
January 8, 2019
Publication date:
November 5, 2020
Applicant:
EpicentRx, Inc.
Inventors:
Bryan T. ORONSKY, Amold ORONSKY, Tony R. REID
Abstract: Compositions comprising an AhR agonist compound, such as indigo and/or an indigo derivative, such as indirubin and isatin, are described. Methods of treatment, including the treatment of ulcerative colitis, by administering the compositions are described. In an embodiment, compositions in the form of a solid amorphous dispersion of the AhR agonist are described.
Type:
Application
Filed:
June 3, 2020
Publication date:
November 5, 2020
Inventors:
Julie Patricia Saiki, Matthew Davidson, Johan Oscar Lennart Andreasson, Michael David Favero, Matthew Benjamin Greene
Abstract: Disclosed herein are compositions and methods for treating cancer. More particularly, the present disclosure relates to compositions and methods for treating cancer including prostate cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid cancer, sarcoma breast cancer, and gastrointestinal stromal tumor. The present disclosure also relates to methods for identifying subjects having drug resistant prostate cancer and drug resistant renal cell carcinoma.
Abstract: The present disclosure relates to an antiaging composition containing cytochalasin D or SAG, and a method for screening an antiaging substance, and provides a new antiaging substance and a new method for discovering a new antiaging substance. Thus, it is possible to greatly contribute to the development of beauty industries and to meeting demands related with beauty and antiaging, if the present disclosure is effectively used.
Type:
Application
Filed:
July 24, 2018
Publication date:
November 5, 2020
Applicant:
AMOREPACIFIC CORPORATION
Inventors:
Hyun Jung CHOI, Hyoung June KIM, Ji Yong JUNG, Tae Ryong LEE
Abstract: The present invention addresses the problem of providing a novel therapeutic agent for keratoconjunctive disorders. As a means for solving the problem, a therapeutic agent for keratoconjunctive disorders which contains a RAR? agonist as an active ingredient is provided. The therapeutic agent exhibits an excellent ameliorating effect in a keratoconjunctive disorder model, and is therefore useful as a therapeutic agent for keratoconjunctive disorders such as corneal ulcer, corneal epithelial abrasion, keratitis, dry eye, conjunctivitis, chronic superficial keratitis, corneal erosion, persistent corneal disorders, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis, filamentary keratoconjunctivitis, infectious keratitis, noninfectious keratitis, infectious conjunctivitis and noninfectious conjunctivitis.
Abstract: Provided are topical analgesic compositions and methods of preparing topical analgesic compositions comprising a stable nano-encapsulating matrix film. The topical analgesic compositions and methods of preparing topical analgesic compositions may be suited for roll-on applicators. Topical analgesic compositions may include 12 to 16 wt. % menthol; 4 to 8 wt. % camphor; 2 to 15 wt. % film-forming polymer; and 50 to 70 wt. % solvent. To be used in a roll-on applicator, the topical analgesic composition has a viscosity from 800 to 1400 centipoise.
Type:
Application
Filed:
April 23, 2020
Publication date:
November 5, 2020
Inventors:
Debanjan DAS, Emanuel VIZZOTTI, Thomas DANN, Renee NELSON, Courtney C. HAYNES, Soundarya VAITHIANATHAN, Reginald BRADLEY, Reinhard WALTER, Gerard MEISEL
Abstract: The present invention relates generally to the use of compositions and methods for treating nociceptive events that occur on the ocular surface in association with dryness, injury, environmental pollutants, and infectious and non-infectious diseases. Specifically, the present invention is directed to the use of certain compounds for treating for treating ocular pain or ocular discomfort.
Abstract: The present disclosure related to methods of treating pruritus in a subject by topically administering detomidine, or a pharmaceutically acceptable salt thereof, to the subject.
Type:
Application
Filed:
May 1, 2020
Publication date:
November 5, 2020
Inventors:
Yael Rosen, David Dangoor, Richard Fisher
Abstract: The present disclosure provides compounds, or a pharmaceutically acceptable salt thereof as described herein, useful for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a subject. The disclosure also provides pharmaceutical compositions comprising these compounds, processes for preparing them, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a subject using these compounds. The present disclosure also provides compounds, or a pharmaceutically acceptable salt thereof as described herein, useful for treating the proliferation of a coronavirus, treating coronavirus symptoms or delaying the onset of coronavirus symptoms in a subject.
Abstract: A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease.
Abstract: The present invention relates to a beta-lactam antibiotic for use in a method of treating a bacterial infection in a subject in need thereof wherein said bacterial infection is caused by a bacterial species characterized by using the mevalonate synthetic pathway, wherein said subject is further treated, before or simultaneously to said beta-lactam antibiotic, with a statin, wherein said statin is for use in reducing, mitigating or reversing resistance to said beta-lactam antibiotic in resistant bacterial populations of said bacterial species.
Abstract: Methods for removing excess free ?-globin in erythroid cells and treating a thalassemia using an agent that activates Unc-51 Like autophagy activating Kinase (ULK) are described.
Type:
Application
Filed:
October 26, 2018
Publication date:
November 5, 2020
Inventors:
Mitchell J. Weiss, Mondira Kundu, Christophe Lechauve
Abstract: A method of preventing or treating an immunological or inflammatory disease or disorder comprising administering a composition including a combination of rapamycin and metformin, wherein the molar ratio of rapamycin to metformin is in the range of about 20:1 to about 1:1; 10:1 to about 4:1; 5:1 to about 3:1; or about 5:1 to about 4:1. The composition may be formulated for oral administration, topical administration, parenteral administration, etc.
Abstract: The present invention provides methods of treating hematological disorders and solid malignant tumors, using substituted indazole compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and BCL-2 kinases.
Abstract: Described herein is (4R,7,S)-2-(3-(4-chlorophenyl)ureido)-9-methyl-5,6,7,8-tetrahydro-4H-4,7-epiminocyclohepta[b]thiophene-3-carboxamide mesylate, including crystalline forms and solvates thereof.
Type:
Application
Filed:
August 31, 2018
Publication date:
November 5, 2020
Applicant:
University of Washington
Inventors:
Graham Johnson, Edwin Aret, Alexei Tchesnokov
Abstract: The invention relates to amide-derivatives of 2-hydroxy-2-methyl-4-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-butanoic acid for use in a treatment for preventing or suppressing symptoms mediated by enhanced mPGES-1 expression or activity. In particular the invention relates the use of these compounds for treating diseases and conditions in which the inhibition of the enzyme mPGES-1 activity and/or expression would be beneficial such as inflammatory diseases, nociceptive pain, auto-immune diseases, breathing disorders, fever, cancer, inflammation related anorexia, Alzheimer's disease and cardiovascular disease.
Type:
Application
Filed:
November 22, 2018
Publication date:
November 5, 2020
Applicant:
Khondrion IP B.V.
Inventors:
Johannes Albertus Maria Smeitink, Julien David Beyrath
Abstract: Many Gram-negative pathogens assemble adhesive pili structures on their surfaces that allow them to colonize host tissues and cause disease. The present invention relates to novel compounds that disrupt the intramolecular interactions of the pilus subunits thereby reducing pilus assembly.
Type:
Application
Filed:
January 27, 2020
Publication date:
November 5, 2020
Inventors:
Scott HULTGREN, Natalie OMATTAGE, Fredrik ALMQVIST, Jerome PINKNER, Karen DODSON, Peng YUAN
Abstract: The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.
Type:
Application
Filed:
April 13, 2020
Publication date:
November 5, 2020
Applicant:
Ferring International Center S.A.
Inventors:
Bong Gil NAM, Byeung Jun LEE, Shunji JIN
Abstract: The present invention provides a medicament comprising a compound represented by general formula (1) which has Axl inhibitory activity, and an EGFR tyrosine kinase inhibitor in combination, and a method for treating cancer using this combination. The present invention provides an excellent medicament and method for treating cancer which is highly effective for inhibiting resistance to an EGFR tyrosine kinase inhibitor in cancer treatment, and causes less adverse reactions such as weight loss.
Abstract: Compositions and methods for treating epilepsy and epileptic syndromes are described herein. The compositions and methods include therapeutically effective amounts of one or more dimebolins, or pharmaceutically acceptable salts thereof.
Abstract: Provided herein are solid forms comprising {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders.
Type:
Application
Filed:
February 10, 2020
Publication date:
November 5, 2020
Inventors:
James Densmore Copp, Ann W. Newman, Anne Luong
Abstract: A small molecule compound IODVA1 has been found to have cellular inhibitory activity against several transformed cell lines including Ras-driven cells. IODVA1 decreases cell-cell and cell-extra cellular matrix interactions and reduces growth of Ras-driven tumors. Applicants also synthesized compound NIRA2 and showed in vitro and in vivo efficacy and potency against models of Ph+(BCR-ABL1) B-ALL and of colon adenocarcinoma xenografts.
Type:
Application
Filed:
May 1, 2020
Publication date:
November 5, 2020
Inventors:
Nicolas Nassar, William Seibel, Anjelika Gasilina, Jose Cancelas
Abstract: The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.
Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
Type:
Application
Filed:
July 13, 2020
Publication date:
November 5, 2020
Applicants:
DANA-FARBER CANCER INSTITUTE, INC.
Inventors:
Leigh ZAWEL, Christopher S. STRAUB, Brant G. FIRESTONE, Glenn DRANOFF, Michael DOUGAN
Abstract: Ligands of the mu, kappa, and delta opioid receptors and methods of using them are disclosed. In particular, the invention relates to the discovery of new opioid receptor ligands based on molecular dynamics simulations of conformational states of the ? opioid receptor and the use of the identified opioid receptor ligands as analgesics, anti-diarrheal agents, and overdose reversal agents.
Type:
Application
Filed:
November 14, 2018
Publication date:
November 5, 2020
Inventors:
Evan N. Feinberg, Vijay S. Pande, Susruta Majumdar, Gavril Pasternak
Abstract: The present invention provides novel 4-methylsulphone-substituted piperidine urea compounds that are useful for the treatment of dilated cardiomyopathy (DCM) and conditions associated with left and/or right ventricular systolic dysfunction or systolic reserve. The synthesis and characterization of the compounds is described, as well as methods for treating DCM and other forms of heart disease.
Type:
Application
Filed:
July 21, 2020
Publication date:
November 5, 2020
Inventors:
Johan Oslob, Danielle Aubele, Jae Kim, Robert McDowell, Yonghong Song, Arvinder Sran, Min Zhong
Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
Type:
Application
Filed:
December 18, 2019
Publication date:
November 5, 2020
Applicant:
AbbVie Inc.
Inventors:
Le WANG, George DOHERTY, Xilu WANG, Zhi-Fu TAO, Milan BRUNCKO, Aaron R. KUNZER, Michael D. WENDT, Xiaohong SONG, Robin FREY, Todd M. HANSEN, Gerard M. SULLIVAN, Andrew JUDD, Andrew SOUERS
Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.
Type:
Application
Filed:
May 22, 2020
Publication date:
November 5, 2020
Inventors:
Fredrik Tiberg, Ian Harwigsson, Markus Johnsson
Abstract: Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.
Abstract: The present disclosure relates to devices for deterring drug abuse and methods thereof. More particularly, the disclosure relates to devices for deterring drug abuse by using physical deterrents and/or deterrent substances, including a mechanism that releases a deterrent substance when improper access of the drug is attempted, and methods thereof.
Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.
Type:
Application
Filed:
July 17, 2020
Publication date:
November 5, 2020
Inventors:
Jane HIRSH, Alison FLEMING, Roman RARIY, Alexander KLIBANOV
Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
Type:
Application
Filed:
July 17, 2020
Publication date:
November 5, 2020
Inventors:
Roman V. RARIY, Alison B. FLEMING, Jane HIRSH, Alexander M. KLIBANOV
Abstract: The present invention is directed to a depot composition for sustained release delivery of buprenorphine with enhanced stability and bioavailability. The composition is an injectable, low viscosity liquid and can form a depot in situ capable of delivering therapeutic level of buprenorphine over a period of time from one week to 3 months.
Abstract: This disclosure is directed to compounds, compositions, and methods for the treatment of various diseases and/or conditions related to G protein-coupled receptor 174 (e.g., cancers).
Type:
Application
Filed:
January 10, 2020
Publication date:
November 5, 2020
Inventors:
Michael Cicirelli, Neil S. Cutshall, Gregory A. Demopulos, George A. Gaitanaris, Marc A. Gavin, Alexander Gragerov, Thomas L. Little, Rene Onrust
Abstract: The disclosure relates to methods for treating or preventing an Insomnia Disorder by administering to a human in need thereof a compound of formula (I), or a compound of formula (IA), (IB), or (IC), or a solvate thereof, in a daily dose of from about 0.5 mg to about 6.0 mg. In certain embodiments, such compounds effectively treat or prevent an Insomnia Disorder in the animal, while producing reduced side effects compared to previously available compounds.
Type:
Application
Filed:
January 22, 2019
Publication date:
November 5, 2020
Applicant:
Purdue Pharma L.P.
Inventors:
Stephen C. HARRIS, Ram P. KAPIL, Donald J. KYLE, Garth WHITESIDE
Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
Type:
Application
Filed:
November 2, 2018
Publication date:
November 5, 2020
Inventors:
Kathleen Ann Martin, Carmela Sidrauski, Jennifer M. Frost, Marina Pliushchev, Yunsong Tong, Lawrence A. Black, Xiangdong Xu, Lei Shi, Qingwei I. Zhang, SeungWon Chung, Ramzi Farah Sweis, Michael J. Dart, John T. Randolph, Kathleen J. Murauski
Abstract: The present invention relates to a composition for preventing or treating atherosclerosis in a subject, comprising a zinc salt and cyclo-Hispro and a method of preventing or treating atherosclerosis using thereof.
Type:
Application
Filed:
April 30, 2019
Publication date:
November 5, 2020
Applicants:
NovMetaPharma Co., Ltd., The United States Government as Represented by the Department of Veterans Affairs
Inventors:
Moon Ki Song, Mysore S. Veena, David Scott Bischoff, Dean Takao Yamaguchi
Abstract: Provided are a compound that is useful for the prevention of and/or as a treatment agent for a disease in which a group II mGlu receptor is involved; and a medical application of said compound. Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
Abstract: Disclosed herein are pharmaceutical compositions, devices, their combinations, and their uses thereof for example in treating or preventing headaches.
Type:
Application
Filed:
July 20, 2020
Publication date:
November 5, 2020
Inventors:
John KOLLINS, Fumiyoshi IWASHIMA, Detlef ALBRECHT, Robert David SCHULTZ
Abstract: Provided herein are methods of treating diseases and disorder responsive to the inhibition of PDE4 comprising administering apremilast and a Tyk2 inhibitor to a subject. Also provided herein are pharmaceutical compositions comprising apremilast and a Tyk2 inhibitor.
Type:
Application
Filed:
April 30, 2019
Publication date:
November 5, 2020
Inventors:
Peter Henry Schafer, Robert Plenge, Mary Adams, Lisa Beebe, Gilles Buchwalter, Tiffany Carr, Te-chen Tzeng
Abstract: The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Type:
Application
Filed:
July 21, 2020
Publication date:
November 5, 2020
Inventors:
Atwood Kim CHEUNG, Donovan Noel CHIN, Natalie DALES, Aleem FAZAL, Timothy Brian HURLEY, John KERRIGAN, Gary O'BRIEN, Lei SHU, Robert SUN, Moo Je SUNG
Abstract: The present invention concerns the microbicidal activity of certain pyrimidine or triazine containing non-nucleoside reverse transcriptase inhibitors. The compounds of the present invention inhibit the systemic infection of a human being with HIV, in particular, the present compounds prevent sexual HIV transmission in humans.
Type:
Application
Filed:
July 16, 2020
Publication date:
November 5, 2020
Inventors:
Jens Marcel Van Roey, Marie-Pierre T.M.M.G. De Bethune, Paul Stoffels